Factors Associated with Rapidly Deteriorating Myelopathy in Patients with Spinal Arteriovenous Shunts

Takahiro MIYAHARA,1,2 Gohsuke HATTORI,1 Hisaaki UCHIKADO,1,3 Yasuyuki KAKU,4 Yuki OHMORI,4 Kimihiko ORITO,1 Yasuharu TAKEUCHI,1 Takayuki KAWANO,1,4 Masaru HIROHATA,1 Akitake MUKASA,4 and Motohiro MORIOKA1

1Department of Neurosurgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan
2Yame General Hospital, Yame, Fukuoka, Japan
3Uchikado Neurospine Clinic, Fukuoka, Fukuoka, Japan
4Department of Neurosurgery, Kumamoto University School of Medicine, Kumamoto, Kumamoto, Japan

Abstract

Spinal arteriovenous (AV) shunts are rare conditions that sometimes present with myelopathy symptoms. The progression of the symptoms is usually gradual; however, some cases show rapid deterioration. We retrospectively investigated the factors that induced the rapid deterioration of myelopathy symptoms in patients with spinal AV shunts. We treated 33 patients with myelopathy with spinal AV shunts at our institutions, eight of whom experienced rapid deterioration (within 24 hours: 24.2%). Of these, three were related to the body movement or particular postures associated with playing golf, 30 minutes of Japanese straight sitting, and massage care. One patient showed deterioration after embolization for a tracheal aneurysm. The remaining four patients received steroid pulse therapy (high-dose steroid infusion) shortly before the rapid deterioration. These symptoms stopped progressing after cessation of steroid use. While positional or physical factors contributing to myelopathy deterioration might exist, we could not identify specific factors in this study. Nevertheless, rapid deterioration was frequently observed after high-dose steroid use. We must take care not to administer high-dose steroids for myelopathy caused by spinal AV shunt disease.

Keywords: spinal arteriovenous shunts, myelopathy, steroid

Introduction

Spinal arteriovenous (AV) shunts or malformations (abnormal connections between arteries and veins of the spine) are rare, and they are classified with classification systems such as dural arteriovenous fistula (AVF), intradural intramedullary glomus arteriovenous malformation (AVM), intradural intramedullary juvenile AVM, perimedullary AVF, and extradural AVF.1,2 Of these, spinal dural arteriovenous fistulas (SDAVFs) are the most common vascular malformations of the spinal cord and its coverings.3 Generally thought to be an acquired lesion, SDAVFs consist of an abnormal and direct connection between the dural branch of a radicular artery and a radicular vein along the inner dural surface, typically lateral to the intervertebral foramen near the nerve root. Venous drainage occurs in a retrograde fashion from the radicular vein into the perimedullary venous plexus. Once these veins become “arterialized” and their pressure increases, the normal anterograde venous drainage of the spinal cord is compromised. Arterialization of the perimedullary venous plexus results in venous congestion of the spinal cord and myelopathy, and in some cases, spinal cord infarction.1-3

The precise diagnosis of myelopathy caused by spinal AV shunt disease remains very difficult because the clinical features and noninvasive imaging results may be nonspecific. Intramedullary high-intensity lesions in magnetic resonance (MR) images are often erroneously diagnosed as a variety of other
diseases. As a result, it often takes a long time (some months or more) to diagnose. Myelopathy symptoms caused by AV shunt disease progress slowly in most cases. Symptoms include lower extremity weakness and sensory impairment, pain, gait disturbance, and urinary and bowel dysfunction. However, in some cases, there is rapid progression during the time course to final diagnosis. To avoid this rapid deterioration in future patients, we reviewed previous medical records and investigated the factors that caused rapid deterioration of myelopathy in patients with spinal AV shunts.

Patients and Methods
We retrospectively reviewed the medical records of patients with spinal AVF with myelopathy who were treated at Kurume University Hospital and Kumamoto University Hospital from January 2010 to May 2020. Patients with hemorrhagic events were excluded. Each patient’s symptoms and clinical course recorded in summary and charts were investigated. The contributing factors to rapid deterioration were examined. We defined rapid deterioration of myelopathy as follows: within 24 hours after a definite event, there was remarkable deterioration manifesting as paresis, sensory disturbance, gait disturbance, or urinary and bowel dysfunction. We defined subacute deterioration of myelopathy as deterioration occurring within 1–3 days after a definite event.

Statistical analyses
Statistical analyses were performed between cases of rapid deterioration and other cases in terms of sex, lesion level (categorized into three groups: craniocervical junction and cervical, thoracic, lumbar and sacral lesion), age, worst manual muscle test (MMT) before surgical interventions, and symptom duration. All statistical analyses were conducted using commercially available software (JMP v16.0; SAS Institute, Cary, NC, USA), and the significance level was set at p < 0.05.

This clinical study was reviewed and approved by the institutional ethical committee of Kurume University (No. 2020-012) and Kumamoto University (No. 1760).

Results

Characteristics of patients
We found 33 patients with myelopathy caused by spinal AV shunt disease (ten at Kurume University Hospital and 23 at Kumamoto University Hospital). Of the 33 patients, the sex distribution was 28 men and five women. The age distribution was 43–84 years (mean 65.9 years). Spinal AV shunts were located at the craniocervical junction in four, cervical in one, thoracic in 18, lumbar in ten, and sacral in two (one patient had double spinal lesions, and this was reported previously). The most frequent spinal AV shunts were SDAVFs (26/33, 78%); some patients had other types of spinal AV shunts, four cases of perimedullary AVF and three cases of extradural AVF. The most frequent symptom was motor weakness (93.9%), followed by gait disturbance (90.0%), sensory disturbance (81.8%), and urinary sphincter dysfunction (51.5%) (Table 1).

Factors contributing to deteriorations
Eight patients had episodes of rapid deterioration of myelopathy (Tables 1 and 2). Of these, three patients showed rapid deterioration after ordinary nonspecific activities: one after playing golf, one (a calligrapher) deteriorated after sitting erect with his legs folded (Japanese proper sitting position) for 30 minutes, and one case after massage care (shown in Table 3). The other four patients deteriorated after steroid pulse therapy. The remaining patient rapidly deteriorated immediately after embolization for tracheal aneurysm in another hospital, which may have been caused by altered flow that exacerbated the spinal AV shunt symptom. In this study, two institutes (Kurume University and Kumamoto University) cared for two patients who showed rapid deterioration after steroid pulse. After these experiences, no steroid pulse treatment was performed for patients suspected of having spinal AVF disease.

Three patients had episodes of subacute (1–3 days) deterioration of myelopathy after some events. Of these three patients, one deteriorated after low-dose steroid use, one deteriorated after administration of prostaglandin E₁ (PGE₁), and one deteriorated after climbing stairs.

The results of statistical analyses showed no significant differences in sex (p = 1.000), lesion level (p = 0.7289), age (p = 0.6418), and symptom duration (p = 0.7503) between patients who experienced rapid deterioration and those who did not. However, significant difference was found in worst MMT before surgical interventions (p = 0.0354).

Case presentations
Case 1, a 72-year-old man: The patient underwent laminoplasty previously for cervical ossification of posterior longitudinal ligament. Lower extremity weakness and urinary retention occurred 8 years later. The symptoms gradually worsened despite having received physical therapy at another hospital. Magnetic resonance imaging (MRI) revealed hyperintensity at the medulla and cervical cord (Fig. 1A).
Table 1  Clinical data of the 33 patients with myelopathy caused by spinal AVF disease

| Sex (F:M) | 5:28 (male: 84.8%) |
|---|---|
| Age (mean) | 65.9 years (43–84 years) |
| Time to diagnosis (mean) | 19.5 months (4 days–10 years) |
| Location of AV shunt | |
| Craniocervical junction | 4 (11.4%) |
| Cervical | 1 (2.8%) |
| Thoracic | 18 (51.4%) |
| Lumbar | 10 (28.5%) |
| Sacral | 2 (5.7%) |

| Symptoms | |
|---|---|
| Weakness | 31 (93.9%) |
| Gait disturbance | 30 (90.0%) |
| Sensory disturbance | 27 (81.8%) |
| Urinary sphincter dysfunction | 17 (51.5%) |

Deterioration pattern
1) Rapid (<24 h), n = 8
   - Ordinary activity
   - Golf
   - Japanese sitting 30 min
   - Massage care
   - Medical procedure
   - Other lesion embolization
   - Steroid pulse

2) Subacute (1–3 days), n = 4
   - Ordinary activity
   - Climbing up stairs
   - Medical procedure
   - Steroid (low dose)
   - PGE1 agent

AVF: arteriovenous fistula, F: female, M: male, AV: arteriovenous, PGE1: prostaglandin E1.

Table 2  Summary of four cases deteriorated during ordinary daily activities

| Sex | Age (years) | Level | Symptoms | Induced activities | Deteriorating course |
|---|---|---|---|---|---|
| M  | 61  | Th7 | L/E weakness and sensory impairment, gait disturbance, urinary sphincter dysfunction | Golf | Rapid |
| M  | 74  | L4  | L/E weakness, gait disturbance | Massage | Rapid |
| M  | 75  | Th6 | L/E weakness and sensory impairment, gait disturbance | Sitting | Rapid |
| F  | 43  | Th7, Th8, Th9, Th12, L3 | L/E weakness, urinary sphincter deterioration | Climbing stairs | Subacute |

M: male, F: female, L/E: lower extremity.
T. Miyahara et al.

Table 3  Lower extremity MMT and other symptoms before and after the event of rapidly deteriorated patients

|   | Before |          | After |          |
|---|--------|----------|-------|----------|
|   | L/E MMT | Others   | L/E MMT | Others   |
| 1 (Steroid) | 4 | S, P | 3 | S, P |
| 2 (Tracheal aneurysm embolization) | 4 | | 3 | U |
| 3 (Steroid) | 3 | S, U | 0–1 | S, U |
| 4 (Steroid) | 4–5 | | 3 | U |
| 5 (Steroid) | 4 | S, U | 0–1 | S, U |
| 6 (Sitting) | 4–5 | S | 3 | S |
| 7 (Golf) | 5 | S | 4 | S, U |
| 8 (Massage) | 4–5 | | 3 | |

MMT: manual muscle test, L/E: lower extremity, S: sensory disturbance, P: pain, U: urinary impairment.

SDAVF was suspected, and the patient was referred to our service. The symptoms rapidly worsened (hemiparesis MMT 3 ⇒ tetraparesis MMT 1) after administration of steroids (betamethasone 1000 mg/day for 3 days). Emergent angiography revealed SDAVF at the cervico-medullary junction. The patient's symptoms gradually resolved after surgical treatment and physical therapy.

Case 2, a 45-year-old woman: The patient was hospitalized at another hospital because of motor weakness, pain, dysesthesia, and hyperreflexia in both lower extremities and gait disturbance; she was suspected of having multiple sclerosis. Initial MR T2-weighted images depicted intramedullary high intensity at Th8 and Th9 (Fig. 2). The patient's motor and sensory disturbance worsened (MMT 4 to 3) after administration of methylprednisolone (1000 mg/day for 3 days). Emergent reexamination of MRI was performed, and spinal AVF was suspected based on the findings of the small vessels around the spinal cord. The patient was referred to our hospital, and surgery was performed. The symptoms ameliorated after stopping the steroids and gradually relieved after surgical treatment and physical therapy.
Fig. 2 (Case 3 in Table 4) (A and B) T2WI of MRI at first admission at the thoracic region. (C) Emergent MRI of T2WI after rapid deterioration following steroid pulse treatment. (D) Angiography revealing a perimedullary AVF. 45-year-old woman: The patient complained of motor weakness, pain, dysesthesia, and hyperreflexia in both lower extremities and gait disturbance, and MR T2WI showed intramedullary high intensity at Th 8 and 9 (A and B). In the first hospital, she was suspected of having multiple sclerosis and was administered methylprednisolone (1000 mg/day for 3 days); however, her motor and sensory disturbance worsened (MMT 4 to 3) the same day. Emergent reexamination of MRI was performed, and spinal AVF disease was suspected based on the findings of the small vessels around the spinal cord (C). The patient was referred to our hospital and surgery was performed. AVF: arteriovenous fistula, MMT: manual muscle test, MR: magnetic resonance, MRI: magnetic resonance imaging, T2WI: T2-weighted image.
Discussion

Pathological AV shunt leads to arterialization of the valveless perimedullary venous plexus, resulting in a reduction in the AV gradient, leading to reduced outflow from the radicular vein, retrograde venous drainage, and intramedullary edema due to venous hypertension. Several studies have demonstrated that venous hypertension and hypervolemia at the DAVF level result in stagnation of blood flow and reduction in the AV gradient, which results in reduced intramedullary blood flow, edema, and ischemia. This pathological condition causes myelopathy resulting in paresis, sensory disturbance, gait disturbance, or urinary and bowel dysfunction.

These symptoms gradually progress. Contributing factors to the deterioration include the following: prolonged standing and walking, related to the Valsalva maneuver, and abdominal compression during lumbar surgery. Most patients show gradual or slow progression of these symptoms, although there are many opportunities for walking/standing and Valsalva maneuver-like conditions. Nevertheless, a few patients show rapid deterioration of these myelopathy symptoms, and the detailed mechanisms and inciting conditions remain unclear. Jellema et al. reported the clinical features of 80 cases of SADVFs. Four patients had an acute onset of symptoms, and the authors noted that acute deterioration occurred most often after exercise; however, in some cases, it occurred after a period of rest. In our study, rapid and subacute deteriorations occurred after golf, sitting, climbing stairs, and massage care. These actions might induce an increased abdominal pressure; however, all actions were general activities of every person and were not specific.

The locations of these four cases were below the T6 level. Increasing intra-abdominal pressure might play a role in contributing to the deterioration of symptoms.

The veins contain approximately 70% of the total blood volume and are 30 times more compliant than arteries. An increase in intra-abdominal pressure may increase intramural and transmural central venous pressure directly via a shift of blood volume from the splanchnic vasculature through the inferior vena cava to the right heart and indirectly (only intramural central venous pressure) via a shift of the diaphragm upward and associated increase in intra-thoracic pressure.

Although deterioration does not occur in spinal AVF shunts even with other daily activities causing higher intra-abdominal pressure (e.g., cough, jumping), we speculate that the flow of arterialized medullary veins further stagnated under increasing intra-abdominal pressure with commencement of ordinary daily activities, and some cases may deteriorate myelopathy. For these reasons, early diagnosis is necessary even when the symptoms are not particularly severe.

In clinical settings, unexplained progressive myelopathy should raise a suspicion of spinal AV shunt. The diagnosis is difficult because the presenting clinical features are often nonspecific and can mimic disorders such as spinal stenosis, demyelinating disease, and medullary tumors. In situations where rapid progression occurs in patients with spinal AV shunt or undiagnosed intramedullary high-intensity lesions, steroid administration is sometimes considered because steroids are somewhat useful in various other diseases.

The main etiology of SDAVF is vasogenic edema, which is why clinicians hope that steroids will benefit the situation. However, steroids have the effects of inhibiting vascular permeability and fluid retention through leukotriene C/D, bradykinin, serotonin, and PGE. The usefulness of steroids for myelopathy in SDAVF has not been established; the issue is also controversial. In the present study, the rapid deterioration rate after steroid pulse therapy was 100% (four of all four cases). Seven case reports have been published about rapidly exacerbating symptoms after adrenocorticotropic hormone or steroid administration to SDAVF. All 11 cases including our four cases are summarized in Table 4. All cases showed rapid deterioration. While most cases showed relatively good outcomes after steroid cessation and early surgery, two patients showed mild or poor improvement. The mechanism of steroid-induced deterioration hypothesizes that steroid administration causes oncotic shifts and/or altered renal dynamics leading to water reabsorption and preferential shunting of blood into the venous circulation.

This rapid deterioration and recovery might be considered a natural course and cured by surgical interventions, not related to the effect of steroids. In our series, there was no case of having steroid therapy without surgical intervention; therefore, such presumption was not completely excluded. However, previously reported cases showed rapid deterioration with steroid use and immediate recovery after cessation of steroid use, without any surgical intervention. In this study, all of our cases in which steroid was used had a rapid and subacute deterioration. Hence, we highly postulate that steroid acts as a strong adverse effect to spinal AVF.

In addition, we also observed subacute deterioration after administration of PGE, in another patient (Fig. 3). Other five patients had also taken PGE.
Table 4  Summary of previously reported cases and our cases showing rapid deterioration after steroid pulse treatment

| No.  | Age (years)/sex | Level                      | Symptoms                                      | Steroids                  | Symptoms after steroid use | Treatments                                      | Postop. course   |
|------|-----------------|----------------------------|-----------------------------------------------|---------------------------|----------------------------|-------------------------------------------------|-----------------|
| Söderlund<sup>23</sup> | 63/M Intracranial | Myelopathy including lower extremities | Methylprednisolone | Worsened, bilateral paraparesis | Steroid discontinuation | Recovery                                        |                 |
| Cabrera<sup>24</sup>   | 62/M L2         | Lower extremities weakness and sensory disturbance, dysuria, constipation | Methylprednisolone | Worsened, bilateral paraparesis, pain | Steroid discontinuation | ?                                               |                 |
| McLeod<sup>25</sup>   | 52/M Intracranial | Bilateral paraparesis, urinary retention | Prednisone/methylprednisolone | Worsened, flaccid paraplegia, urinary retention | Steroid discontinuation, surgical obliteration | Improved                                                   |                 |
| McLeod<sup>26</sup>   | 51/F L3         | Slowly progressive myelopathy | Methylprednisolone | Worsened, bilateral paraparesis | Steroid discontinuation, nonradiographic disconnection | Recovery, MMT 0 ⇒ 4                                   |                 |
| McLeod<sup>26</sup>   | 58/F L2         | Progressive lower extremities weakness and sensory disturbance | Methylprednisolone | Worsened rapidly, bilateral paraparesis | Steroid discontinuation, surgical treatment | Recovery, MMT 0 ⇒ 4                                   |                 |
| Strowd<sup>27</sup>   | 45/M L3         | Allergic reaction, no neurological deficit | Prednisone/methylprednisolone | Worsened rapidly, bilateral paraparesis, urinary retention, sexual dysfunction | Steroid discontinuation, surgical treatment | Recovery, MMT 0 ⇒ 4                                   |                 |
| Disano<sup>28</sup>   | 63/F L2         | Lower extremity sensory disturbance and clonus, urinary retention | Methylprednisolone | Worsened rapidly, paraparesis, sensory disturbance | Steroid discontinuation, improvement surgical treatment | Mild improvement, MMT 3 ⇒ 4                          |                 |
| Case1              | 72/M Craniocervical junction | Rt. U/E weakness, urinary retention | Betamethasone (pulse) | Worsened rapidly the next day (hemiparesis MMT 3 ⇒ tetraparesis MMT 1) | Steroid discontinuation, surgical occlusion | Recovery, MMT 1 ⇒ 4                                  |                 |
| Case2              | 72/M Craniocervical junction | Tetraparesis, sensory disturbance, urinary incontinence | Methylprednisolone (pulse) | Worsened rapidly on the same day | Steroid discontinuation, surgical occlusion | Recovery, MMT 0 ⇒ 4                                  |                 |
Fig. 3  (A) Intramedullary high-intensity lesion was found from thoracic to conus level on MRI T2WI. Abnormal flow voids were found around the cord. (B) Abnormal perimedullary vein was depicted with CT angiography. (C) Spinal AVF (epidural AVF) at Th7 was depicted with spinal DSA. 58-year-old man: He had a year history of bilateral foot paresthesia. Gait disturbance, mild urinary retention, and constipation occurred gradually. He visited the local clinic and suspected lumbar canal stenosis. The symptoms deteriorated with a few days course with the prescribed PGE₁ agent. Spinal AVF was suspected on lumbar MRI, and he was referred to our service. AVF: arteriovenous fistula, CT: computed tomography, DSA: digital subtraction angiography, MRI: magnetic resonance imaging, PGE₁: prostaglandin E₁, T2WI: T2-weighted image.

| No.  | Age (years)/sex | Level         | Symptoms                                                                 | Steroids                  | Symptoms after steroid use | Treatments                                   | Postop. course |
|------|-----------------|---------------|--------------------------------------------------------------------------|---------------------------|---------------------------|-----------------------------------------------|----------------|
| Case 3 | 45/F            | Conus (perimedullary) | Paraparesis, sensory disturbance, gait disturbance                        | Methylprednisolone (pulse) | Worsened rapidly on the same day | Steroid discontinuation, shunt/feeder surgical occlusion | Recovery, MMT 3 ⇒ 4 |
| Case 4 | 60/M            | Conus (extradural)   | Paraparesis, sensory disturbance, gait disturbance, bladder–rectal impairment | Methylprednisolone (pulse) | Worsened rapidly on the same day | Steroid discontinuation, transarterial embolization | Recovery in sensory, MMT 0 ⇒ 1, hypesthesia below Th10 ⇒ below L4 |

Postop.: postoperative, M: male, F: female, Rt.: right, MMT: manual muscle test, U/E: upper extremity.
agent; however, the relevance of PGE, administration and the time course was not clear. As previously reported, PGE, has a vasodilating effect. With PGE, vasodilating effect, it may be surmised that the mechanism similar to high-dose steroid induced deterioration. We treated two other patients who had taken low-dose steroids and did not experience such rapid deterioration; it may be assumed that the dose-dependent nature of steroid pharmacokinetics proportionally affects the spinal AV shunt.

The presence of a significant number of smooth muscle fibers within the wall of the radicular vein before and behind the dural bottle neck has been reported, and dynamic regulation was suggested by van der Kuip et al.

Thron et al. evaluated 104 specimens obtained from unselected autopsies and did not confirm the presence of valves in the radiculomedullary veins; nevertheless, they confirmed two main types of venous exit through the dura mater: slit type 60%, bulge or nodular type 35%, and the remaining 5% could not be assigned to either one of the main types.

These anatomical studies were normal unselected autopsy cases; nevertheless, such anatomical structures and interactions with the steroid contractile effect smooth muscle, steroid, PGE, and ordinary daily activities may be relevant to the deteriorating mechanism of spinal AVF.

Certainly, the same ordinary daily activities do not always cause the same deterioration reproducively shortly thereafter and in other patients with spinal AV shunt. Ordinary daily activities causing rapid or subacute deteriorations were not the first event for any patient. This may be due to individual variations. Further studies are needed to elucidate more precise mechanisms and factors.

Physicians should keep this pitfall in mind when treating these intramedullary high-intensity lesions until exclusion of the possibility of spinal AV shunt disease.

Furthermore, if spinal AV shunt is diagnosed, steroid use should be avoided, as well as activities that may further increase abdominal pressure. However, as demonstrated by our results and previous report, ordinary daily activities and even rest may sometimes deteriorate the symptoms. Therefore, once spinal AV shunt is diagnosed, early treatments are recommended to prevent progression to neurological deterioration.

**Limitations**

As with most retrospective studies, the lack of prospective enrollment limits the ability to established causality. The small sample size in our series may weaken the robustness of our observations; verification of our findings may ultimately require a large prospective multi-institutional study that would serve to reduce any selection bias associated with the two institutions study and would improve the generalizability of our results.

**Conclusion**

We reviewed patients with spinal AV shunts treated in our institutions and evaluated the factors leading to rapid worsening of myelopathy. Because ordinary actions such as sitting and climbing upstairs may induce rapid deterioration, early diagnosis is necessary. Furthermore, rapid deterioration was induced by the administration of steroid pulse therapy. Therefore, we recommend that high-dose steroid administration should be avoided, especially in patients with intramedullary high-intensity lesions on MRI T2 images, until the possibility of spinal AV shunt disease is excluded.

**Conflicts of Interest Disclosure**

All authors who are members of the Japan Neurosurgical Society (JNS) have registered self-reported COI disclosure statements through the website for JNS. The authors declare no conflicts of interest for this manuscript.

**References**

1) Endo T, Endo H, Sato K, Matsumoto Y, Tominaga T: Surgical and endovascular treatment for spinal arteriovenous malformations. *Neurol Med Chir (Tokyo)* 56: 457–464, 2016

2) Takai K: Spinal Arteriovenous shunts: angioarchitecture and historical changes in classification. *Neurol Med Chir (Tokyo)* 57: 356–365, 2017

3) Aminoff MJ, Logue V: Clinical features of spinal vascular malformations. *Brain* 97: 197–210, 1974

4) Hurst RW, Kenyon LC, Lavi E, Raps EC, Marcotte P: Spinal dural arteriovenous fistula: the pathology of venous hypertensive myelopathy. *Neurology* 45: 1309–1313, 1995

5) Narvid J, Hetts SW, Larsen D, et al.: Spinal dural arteriovenous fistulae: clinical features and long-term results. *Neurosurgery* 62: 159–166; discussion 166–167, 2008

6) Kaku Y, Ohmori Y, Kawano T, Takeshima Y, Kuratsu J: Remote lesions of synchronous sacral and cervical dural arteriovenous fistulas: a case report. *World Neurosurg* 105: 1037.e13–1037.e16, 2017

7) Muralidharan R, Saladino A, Lanzino G, Atkinson JL, Rabinstein AA: The clinical and radiological presentation of spinal dural arteriovenous fistula. *Spine (Phila Pa 1976)* 36: E1641–E1647, 2011
8) Krings T, Geibprasert S: Spinal dural arteriovenous fistulas. AJNR Am J Neuroradiol 30: 639–648, 2009
9) Klopper HB, Surdell DL, Thorell WE: Type I spinal dural arteriovenous fistulas: historical review and illustrative case. Neurosurg Focus 26: E3, 2009
10) Steinmetz MP, Chow MM, Krishnaney AA, et al.: Outcome after the treatment of spinal dural arteriovenous fistulae: a contemporary single-institution series and meta-analysis. Neurosurgery 55: 77–87; discussion 87–88, 2004
11) Takami T, Ohata K, Nishio A, Hara M: Histological characteristics of arterialized medullary vein in spinal dural arteriovenous fistulas related with clinical findings: report of five cases. Neurol India 54: 202–204, 2006
12) Jellema K, Tijssen CC, van Gijn J: Spinal dural arteriovenous fistulas: a congestive myelopathy that initially mimics a peripheral nerve disorder. Brain 129: 3150–3164, 2006
13) Hassler W, Thron A: Flow velocity and pressure measurements in spinal dural arteriovenous fistulas. Neurosurg Rev 17: 29–36, 1994
14) Koch C: Spinal dural arteriovenous fistula. Curr Opin Neurol 19: 69–75, 2006
15) Kataoka H, Miyamoto S, Nagata I, Ueba T, Hashimoto N: Venous congestion is a major cause of neurological deterioration in spinal arteriovenous malformations. Neurosurgery 48: 1224–1229; discussion 1229–1230, 2001
16) Khurana VG, Perez-Torizic CM, Petersen RC, Krauss WE: Singing paraplegia: a distinctive manifestation of a spinal dural arteriovenous fistula. Neurology 58: 1279–1281, 2002
17) Atkinson JL, Miller GM, Krauss WE, et al.: Clinical and radiographic features of dural arteriovenous fistula, a treatable cause of myelopathy. Mayo Clin Proc 76: 1120–1130, 2001
18) Jellema K, Canta LR, Tijssen CC, van Rooij WJ, Koudstaal PJ, van Gijn J: Spinal dural arteriovenous fistulas: clinical features in 80 patients. J Neurol Neurosurg Psychiatry 74: 1438–1440, 2003
19) Gelman S: Venous function and central venous pressure: a physiologic story. Anesthesiology 108: 735–748, 2008
20) Cobb WS, Burns JM, Kercher KW, Matthews BD, James Norton H, Todd Heniford B: Normal intraabdominal pressure in healthy adults. J Surg Res 129: 231–235, 2005
21) Twardowski ZJ, Khanna R, Nolph KD, et al.: Intraabdominal pressures during natural activities in patients treated with continuous ambulatory peritoneal dialysis. Nephron 44: 129–135, 1986
22) Harman EA, Frykman PN, Clagett ER, Kraemer WJ: Intra-abdominal and intra-thoracic pressures during lifting and jumping. Med Sci Sports Exerc 20: 195–201, 1988
23) Strowd RE, Geer C, Powers A, Abou-Zeid N: A unique presentation of a spinal dural arteriovenous fistula exacerbated by steroids. J Clin Neurosci 19: 466–468, 2012
24) Cabrera M, Paradas C, Márquez C, González A: Acute paraparesis following intravenous steroid therapy in a case of dural spinal arteriovenous fistula. J Neurol 255: 1432–1433, 2008
25) O’Keeffe DT, Mikhail MA, Lanzino G, Kallmes DF, Weisnhenker BG: Corticosteroid-induced paraplegia—a diagnostic clue for spinal dural arterial venous fistula. JAMA Neurol 72: 833–834, 2015
26) McKeon A, Lindell EP, Atkinson JL, Weisnhenker BG, Piepgras DG, Pittock SJ: Pearls & oy-sters: clues for spinal dural arteriovenous fistulae. Neurology 76: e10–e12, 2011
27) Söderlund ME, Benisty S, Gaston A, Djindjian M, Cesaro P, Créange A: [Can myelopathies secondary to arterio-venous dural fistulae be aggravated by intravenous corticosteroid therapy?]. Rev Neurol (Paris) 163: 235–237, 2007
28) DiSano MA, Cerejo R, Mays M: Acute paraparesis and sensory loss following intravenous corticosteroid administration in a case of longitudinally extensive transverse myelitis caused by spinal dural arteriovenous fistula: case report and review of literature. Spinal Cord Ser Cases 3: 17025, 2017
29) Bergstrom S, Duner H, von Euler U, Pernow B, Sjovall J: Observations on the effects of infusion of progestin E1 in severe peripheral vascular disease. Lancet 2: 810, 1976
30) Carlson LA, Olsson AG: Intravenous progestin E1 in severe peripheral vascular disease. Lancet 2: 810, 1976
31) Yone K, Sakou T, Kawauchi Y: The effect of Lipo prostaglandin E1 on cauda equina blood flow in patients with lumbar spinal canal stenosis: myeloscopic observation. Spinal Cord 37: 269–274, 1999
32) Pickup ME, Lowe JR, Leatham PA, Rhind VM, Wright V, Downie WW: Dose dependent pharmacokinetics of prednisolone. Eur J Clin Pharmacol 12: 213–219, 1977
33) Rose JQ, Yurchak AM, Jusko WJ: Dose dependent pharmacokinetics of prednisolone and prednisolone in man. J Pharmacokinet Biopharm 9: 389–417, 1981
34) van der Kuip M, Hoogland PV, Groen RJ: Human radicular veins: regulation of venous reflux in the absence of valves. Anat Rec 254: 173–180, 1999
35) Thron A, Krings T, Otto J, Mull M, Schroeder JM: The transdural course of radicular spinal cord veins—a microangiographical and microsopical study. Clin Neuroradiol 25: 361–369, 2015
36) Kornel L, Nelson WA, Manisundaram B, Chugurupati R, Hayashi T: Mechanism of the effects of glucocorticoids and mineralocorticoids on vascular smooth muscle contractility. Steroids 58: 580–587, 1993

Corresponding author: Takahiro Miyahara, MD
Yame General Hospital, 540-2 Takatsuka, Yame, Fukuoka 834-0034, Japan.
e-mail: miya123xwnwk@yahoo.co.jp